or Try an Advanced Search...

    Technical Analysis for ACHL - Achilles Therapeutics plc

    Grade Last Price % Change Price Change
    C 1.05 0.00% 0.00
    ACHL closed unchanged on Thursday, November 7, 2024, on 12 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical ACHL trend table...
    Date Alert Name Type % Chg
    New Uptrend Bullish 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Doji - Bearish? Reversal 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    BB Squeeze Ended Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Older End-of-Day Signals for ACHL ...

       Recent Intraday Alerts

    Alert Time
    Down 1% about 15 hours ago
    60 Minute Opening Range Breakdown about 17 hours ago
    Rose Above Previous Day's High about 17 hours ago
    Up 2% about 17 hours ago
    Fell Below Upper Bollinger Band about 17 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ACHL Chart by TradingView
    Basic chart:

    Profile

    Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Antineoplastic Drugs Melanoma Orphan Drug Breakthrough Therapy Bladder Cancer Head And Neck Cancer Renal Cell Carcinoma Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Immuno Oncology Biopharmaceutical Triple Negative Breast Cancer

    Is ACHL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 23 Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
    Aug 14 Achilles Therapeutics GAAP EPS of -$0.41
    Aug 14 Will Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?
    Aug 14 Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
    May 22 Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
    See more ACHL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.76
    52 Week Low 0.63
    Average Volume 819,334
    200-Day Moving Average 0.93
    50-Day Moving Average 0.92
    20-Day Moving Average 1.00
    10-Day Moving Average 1.02
    Average True Range 0.04
    RSI (14) 67.11
    ADX 25.21
    +DI 20.52
    -DI 9.68
    Chandelier Exit (Long, 3 ATRs) 0.94
    Chandelier Exit (Short, 3 ATRs) 1.07
    Upper Bollinger Bands 1.04
    Lower Bollinger Band 0.96
    Percent B (%b) 1.02
    BandWidth 8.12
    MACD Line 0.03
    MACD Signal Line 0.03
    MACD Histogram -0.0003
    Fundamentals Value
    Market Cap 42.62 Million
    Num Shares 40.8 Million
    EPS -1.90
    Price-to-Earnings (P/E) Ratio -0.55
    Price-to-Sales 0.00
    Price-to-Book 0.25
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.11
    Resistance 3 (R3) 1.11 1.09 1.10
    Resistance 2 (R2) 1.09 1.07 1.09 1.09
    Resistance 1 (R1) 1.07 1.06 1.06 1.07 1.09
    Pivot Point 1.05 1.05 1.04 1.05 1.05
    Support 1 (S1) 1.03 1.03 1.02 1.03 1.00
    Support 2 (S2) 1.01 1.02 1.01 1.00
    Support 3 (S3) 0.99 1.01 1.00
    Support 4 (S4) 0.99